

08 Performance and Corporate Information

- 8-1 Financial Summary 132
- 8-2 Non-Financial Summary 137
- 8-3 Company and Stock Information 139

8-1

Financial Summary

(Consolidated)


	40th Fiscal Year FYE June 2016	41st Fiscal Year FYE June 2017	42nd Fiscal Year FYE June 2018	43rd Fiscal Year FYE June 2019	44th Fiscal Year FYE June 2020	45th Fiscal Year FYE June 2021	46th Fiscal Year FYE June 2022	47th Fiscal Year FYE June 2023	48th Fiscal Year FYE June 2024	49th Fiscal Year FYE June 2025 (Current Fiscal Year)
Net sales (million yen)	39,511	42,709	50,124	57,216	56,546	61,507	77,748	90,101	107,547	120,025
Operating profit excluding goodwill amortization, etc. (million yen)	10,004	10,797	13,774	15,317	12,595	12,944	16,893	19,934	24,168	31,689
EBITDA (million yen)	12,291	13,350	16,660	18,778	16,794	17,764	22,712	26,742	31,856	40,225
Operating profit (million yen)	10,002	10,795	13,773	15,168	12,445	12,795	15,239	18,030	22,135	30,079
Operating profit margin (%)	25.3	25.3	27.5	26.5	22.0	20.8	19.6	20.0	20.6	25.1
Ordinary income (million yen)	9,521	10,941	13,740	14,833	12,310	13,196	16,326	17,635	21,968	29,563
Net income attributable to parent company shareholders (million yen)	6,907	7,725	10,042	11,237	9,178	9,984	10,857	13,106	15,808	12,737
Comprehensive income (million yen)	4,126	9,490	10,623	11,335	9,251	10,753	17,297	16,280	22,873	9,375
Total assets (million yen)	50,286	63,246	72,104	84,358	93,729	115,427	155,127	172,644	191,614	193,187
Net assets (million yen)	32,263	44,659	53,599	65,450	71,975	92,938	121,130	134,300	151,961	151,354
Equipment investment (million yen)	3,836	5,169	8,183	9,702	11,361	11,764	8,933	14,456	12,570	8,447
Depreciation and goodwill amortization (million yen)	2,286	2,552	2,886	3,460	4,198	4,819	6,439	7,513	8,464	9,190
R&D expenses (million yen)	3,886	4,496	5,052	6,036	6,579	7,524	8,869	9,723	11,662	12,248
Net assets per share (yen)	127.47	173.11	207.34	251.37	276.13	349.18	439.80	487.12	556.71	558.31
Earnings per share (yen)	27.31	30.43	38.88	43.29	35.25	38.25	40.01	48.25	58.20	46.92
Equity ratio (%)	64.1	70.6	74.3	77.6	76.8	80.5	77.0	76.6	78.9	77.9
Return On Equity (ROE) (%)	21.3	20.1	20.4	18.9	13.4	12.1	10.2	10.4	11.2	8.4
Return on invested capital (ROIC) (%)	-	-	-	16.4	11.4	9.8	9.1	9.0	10.1	13.1
Price earnings ratio (x)	45.5	42.0	53.9	61.3	87.0	69.4	51.2	58.3	38.8	48.7
Cash flows from operating activities (million yen)	8,622	10,257	11,717	11,720	11,166	8,920	17,302	19,138	34,708	40,543
Cash flows from investing activities (million yen)	-3,841	-5,268	-10,537	-10,849	-10,389	-16,327	-18,703	-15,135	-21,222	-13,434
Cash flows from financing activities (million yen)	-4,552	1,598	-3,749	267	-850	10,110	11,368	-2,342	-13,878	-8,107
Cash and equivalents, end of period (million yen)	12,935	19,992	17,494	18,777	18,554	21,358	32,321	34,884	35,658	53,200
(Reference) Consolidated dividend payout ratio (%)	27.5	25.0	25.0	25.0	25.0	30.0	30.0	30.0	35.0	51.6
Number of employees/consolidated (persons)	5,545	6,220	6,998	7,810	8,761	9,409	10,435	10,187	9,371	9,473

- The company conducted a two-for-one split of its common shares on August 1, 2015; January 1, 2018; and July 1, 2019. Accordingly, the net assets per share and net profit per share are calculated on the assumption that such split of shares was conducted at the beginning of FYE June 2016.
- Return on invested capital (ROIC) is calculated based on the following formula. ROIC is not disclosed for the 42nd fiscal year or earlier.
ROIC = net operating profit after tax / invested capital [interest-bearing debt + shareholders' equity (average of beginning and ending balances)]

8-1 Financial Summary

Trend of Net Sales by Segment

Medical Division has grown significantly owing to improved performance in the overseas market.



8-1 Financial Summary

Net Sales and Operating Profit

Net sales totaled 120,025 million yen (an increase of 11.6% year on year), mainly due to strong sales in the Medical Division both in Japan and overseas thanks to continued market share expansion.


Gross profit totaled 81,235 million yen (an increase of 17.6% year on year) due to the increase in gross profit margin from the increase in net sales and productivity improvement, while there were negative factors such as the appreciation of the Thai baht.

Operating profit was 30,079 million yen (an increase of 35.9% year on year), despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses mainly associated with reinforcement of sales in the non-cardiovascular field in the U.S. and new fields in Japan and an increase in R&D expenses.

Ordinary income was 29,563 million yen (34.6% increase year on year) as a result of the increase in subsidy income despite an increase in exchange losses.

Profit attributable to parent company shareholders was 12,737 million yen (a decrease of 19.4% year on year) as a result of the recording of extraordinary losses such as impairment loss.

Net Sales and Operating Profit



*Effective from FYE June 2025, general and administrative expenses for certain consolidated subsidiaries have been included in corporate expenses. Comparative information has been reclassified accordingly starting from FYE June 2024.

Net Sales by Business Segment and Operating Profit


① Medical Division

In the Medical Division, net sales was brisk and increased owing to continued growth of market share in all regions. In the domestic market, peripheral vascular products (imported purchased products) and neurovascular products were also highly evaluated in the non-cardiovascular field, in addition to the strong performance in the cardiovascular field, resulting in an increase in net sales. In the overseas market, net sales increased in both cardiovascular and non-cardiovascular fields. In the cardiovascular field, net sales performed very strongly in all regions, primarily for PCI guide wires and penetration catheters. In the non-cardiovascular field, net sales increased owing to the strong performance of neurovascular products in the Chinese market and abdominal vascular products in the U.S. market despite a decline in OEM transactions in the U.S. As a result, net sales totaled 107,779 million yen (an increase of 12.7% year on year). Segment profit amounted to 33,445 million yen (an increase of 36.9% year on year).


② Device Division

In the Device Division, net sales increased owing to an increase in medical components, despite a decrease in industrial components. As for medical components, net sales increased mainly owing to increases in transactions of cardiovascular inspection catheter components for Asia. Net sales from industrial components decreased owing to decreases in leisure-related transactions in the overseas market, while domestic and overseas machinery and construction-related transactions increased. As a result, net sales totaled 12,245 million yen (an increase of 3.0% year on year). Segment profit amounted to 4,624 million yen (a decrease of 12.5% year on year) due to a decrease in intersegment transactions.

Medical Division Net Sales and Operating Profit



Device Division Net Sales and Operating Profit



8-1 Financial Summary

Consolidated Balance Sheet

	Previous Fiscal Year (FYE June 2024)	Current Fiscal Year (FYE June 2025)
Assets		
Current assets		
Cash and deposit	35,658	54,200
Bills/accounts receivable	17,676	15,767
Electronically recorded monetary claims – operating	1,913	2,026
Securities	3,000	—
Merchandise and finished goods	9,282	9,408
Work in process	12,298	8,785
Raw materials and supplies	7,763	6,458
Others	7,609	7,004
Allowance for doubtful accounts	- 505	- 291
Total current assets	94,696	103,359
Fixed Assets		
Tangible fixed assets		
Buildings and structures	46,109	49,407
Accumulated depreciation	- 14,523	- 16,884
Buildings and structures, net	31,585	32,523
Machinery, equipment and vehicles	36,239	36,847
Accumulated depreciation	- 25,683	- 28,008
Machinery, equipment, and vehicles, net	10,555	8,838
Land	7,257	7,301
Construction in progress	4,207	3,758
Others	14,463	15,851
Accumulated depreciation	- 7,940	- 9,190
Others, net	6,523	6,661
Total tangible fixed assets	60,129	59,082
Intangible assets		
Goodwill	6,910	110
Others	10,048	5,485
Total intangible assets	16,959	5,595
Investments and other assets		
Investment securities	15,185	19,389
Shares of subsidiaries and associates	220	335
Deferred tax assets	989	1,779
Others	3,538	4,384
Allowance for doubtful accounts	- 105	- 739
Total investments and other assets	19,828	25,149
Total fixed assets	96,917	89,827
Total assets	191,614	193,187

(Million yen)

	Previous Fiscal Year (FYE June 2024)	Current Fiscal Year (FYE June 2025)
Liabilities		
Current liabilities		
Bills payable/accounts payable	2,289	2,655
Electronically recorded obligations – operating	625	424
Short-term debt	5,615	2,387
Account payable – other	4,038	1,805
Accrued corporate tax, etc.	2,683	4,789
Provision for bonuses	2,700	2,868
Others	11,542	12,924
Total current liabilities	29,494	27,856
Fixed liabilities		
Long-term debt	1,087	6,633
Deferred tax liabilities	4,643	1,929
Provision for retirement benefits for Directors (and other officers)	19	19
Retirement benefit liability	2,851	2,943
Asset retirement obligations	17	197
Lease obligations	1,502	2,078
Others	36	174
Total fixed liabilities	10,157	13,976
Total liabilities	39,652	41,833
Net assets		
Shareholders' equity		
Capital stock	18,860	18,860
Capital surplus	21,779	21,779
Retained earnings	90,742	97,947
Treasury stock	- 7	- 4,453
Total shareholders' equity	131,375	134,134
Accumulated other comprehensive income		
Valuation difference on available for-sale securities	2,689	2,008
Foreign currency translation adjustment	17,142	14,315
Re-measurements of defined benefit plans	9	99
Total accumulated other comprehensive income	19,841	16,424
Non-controlling interests	744	795
Total net assets	151,961	151,354
Total liabilities and net assets	191,614	193,187

(Million yen)

Consolidated Statements of Income

	Previous Fiscal Year (FYE June 2024)	Current Fiscal Year (FYE June 2025)
Net sales	107,547	120,025
Cost of sales	38,494	38,789
Gross profit	69,053	81,235
Selling, general, and administrative expenses		
Freight-out	2,748	2,949
Provision of allowance for doubtful accounts	169	58
Salaries and bonuses	11,280	12,926
Director remuneration	767	694
Bonuses for Directors (and other officers)	246	—
Provision of allowance for bonuses	1,291	1,458
Retirement benefit expenses	479	441
Depreciation	2,943	3,002
R&D expenses	11,662	12,248
Others	15,329	17,376
Total selling, general, and administrative expenses	46,917	51,155
Operating profit	22,135	30,079
Non-operating income		
Interest income	102	115
Dividend income	91	128
Subsidy income	79	918
Others	242	239
Total non-operating income	515	1,401
Non-operating expense		
Interest expenses	226	214
Foreign exchange loss	379	1,455
Others	77	247
Total non-operating expense	683	1,918
Ordinary income	21,968	29,563
Extraordinary gain		
Gain on sale of investment securities	21	23
Reversal of allowance for doubtful accounts	—	100
Total extraordinary gain	21	123
Extraordinary loss		
Impairment loss	—	9,244
Loss on valuation of investment securities	99	1,068
Loss on valuation of shares of subsidiaries and associates	—	210
Provision of allowance for doubtful accounts for subsidiaries and associates	—	477
Provision of allowance for doubtful accounts	100	—
Others	0	31
Total extraordinary loss	199	11,031
Profit before income taxes and others	21,789	18,655
Income taxes – current	5,630	9,147
Income taxes – deferred	263	- 3,284
Total income taxes	5,893	5,863
Net income	15,895	12,792
Profit attributable to non-controlling interests	87	54
Profit attributable to parent company shareholders	15,808	12,737

8-1 Financial Summary

Consolidated Statement of Comprehensive Income

	Previous Fiscal Year (FYE June 2024)	Current Fiscal Year (FYE June 2025)
Net income	15,895	12,792
Other comprehensive income		
Valuation difference on available-for-sale securities	656	- 680
Foreign currency translation adjustment	6,274	- 2,826
Re-measurements of defined benefit plans	45	90
Total other comprehensive income	6,977	- 3,417
Comprehensive income	22,873	9,375
(Breakdown)		
Comprehensive income attributable to parent company shareholders	22,684	9,323
Profit attributable to non-controlling interests	188	51

Consolidated Statements of Changes in Shareholders' Equity

Previous Fiscal Year (FYE June 2025)

	Shareholders' equity					Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Re-measurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	18,860	21,727	78,867	- 7	119,448	2,033	10,867	- 36	12,864	1,987	134,300
Changes during the period											- 3,933
Dividends of surplus					- 3,933						- 3,933
Profit attributable to parent company shareholders					15,808						15,808
Acquisition of treasury stock					- 0						- 0
Purchase of shares of consolidated subsidiaries					52						52
Net changes in items other than shareholders' equity						656	6,274	45	6,977	- 1,243	5,733
Total changes during the period					—	52	11,824	- 0	11,927	656	17,660
Balance at the end of the period	18,860	21,779	90,742	- 7	131,375	2,689	17,142	9	19,841	744	151,961

Current Fiscal Year (FYE June 2025)

	Shareholders' equity					Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity	Valuation difference on available-for-sale securities	Foreign currency translation adjustment	Re-measurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at the beginning of current period	18,860	21,779	90,742	- 7	131,375	2,689	17,142	9	19,841	744	151,961
Changes during the period											- 5,533
Dividends of surplus					- 5,533						- 5,533
Profit attributable to parent company shareholders					12,737						12,737
Acquisition of treasury stock					- 4,446						- 4,446
Purchase of shares of consolidated subsidiaries					—						—
Net changes in items other than shareholders' equity						- 680	- 2,826	90	- 3,417	51	- 3,365
Total changes during the period					—	- 4,446	2,758	- 680	- 2,826	90	- 3,417
Balance at the end of the period	18,860	21,779	97,947	- 4,453	134,134	2,008	14,315	99	16,424	795	151,354

Consolidated Statements of Cash flows

	Previous Fiscal Year (FYE June 2024)	Current Fiscal Year (FYE June 2025)
--	-----------------------------------------	----------------------------------------

Cash flows from operating activities

Profit before profit taxes and others	21,789	18,655
Depreciation	8,464	9,190
Impairment loss	—	9,244
Increase (decrease) in allowance for doubtful accounts	273	427
Increase (decrease) in provision for bonuses	837	216
Increase (decrease) in retirement benefit liability	261	418
Interest income and dividend income	- 193	- 244
Interest expenses	226	214
Amortization of goodwill	1,255	955
Loss (gain) on valuation of investment securities	99	1,068
Increase (decrease) in trade and other receivables	- 2,345	1,166
Increase (decrease) in inventories	4,456	3,540
Increase (decrease) in trade and other payables	- 973	190
Increase (decrease) in accounts payable	563	- 851
Increase (decrease) in advances received	4,346	1,679
Increase (decrease) in accrued income	- 337	- 110
Others	1,289	992
Subtotal	40,014	46,756
Interest and dividends received	185	249
Interest paid	- 167	- 248
Income taxes paid	- 5,323	- 6,213
Cash flows from operating activities	34,708	40,543
Cash flows from investing activities		
Purchase of securities	- 3,000	—
Proceeds from redemption of securities	2,000	3,000
Purchase of investment securities	- 8,334	- 14,325
Proceeds from sale of investment securities	61	8,041
Purchase of tangible fixed assets	- 9,877	- 8,096
Purchase of intangible assets	- 667	- 482
Others	- 1,403	- 1,571
Cash flows from investing activities	- 21,222	- 13,434
Cash flows from financing activities		
Net increase (decrease) in short-term debt	- 6,500	- 1,000
Proceeds from long-term loans payable	1,500	8,500
Repayment of long-term loans payable	- 3,202	- 5,182
Dividends paid	- 3,933	- 5,533
Purchase of treasury shares	- 0	- 4,446
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	- 1,355	—
Repayments of lease obligations	- 385	- 446
Cash flows from financing activities	- 13,878	- 8,107
Effect of exchange rate change on cash and cash equivalents	1,164	- 1,459
Increase (decrease) in cash and cash equivalents	773	17,542
Cash and cash equivalents at beginning of period	34,884	35,658
Cash and cash equivalents at end of period	35,658	53,200